Want to see PRCT full AI Analyst Report?
EarningsQ2 2026 Earnings Report
PRCT Q2 2026 EPS Results
Actual EPS-$0.47
Consensus EPS-$0.46
Beat/MissMissed by -<$0.01
One Year Ago EPS-$0.35
PRCT Q2 2026 Revenue Results
Actual Revenue$94.50M
Expected Revenue$92.77M
Beat/MissBeat by +$1.73M
YoY Revenue Growth+19.34%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeAfter Close
Conference CallTuesday, August 4, 2026
PRCT Upcoming Earnings
PROCEPT BioRobotics's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
PRCT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a generally positive outlook driven by strong HYDROS adoption, record pricing, solid top-line growth (Q2 revenue +19% and procedures +21% YoY), important clinical and regulatory milestones, and a clear path to positive adjusted EBITDA in Q4 2026. Offsetting risks include a concentrated procedure shortfall in legacy AQUABEAM accounts, higher operating expenses that widened losses in the quarter, and some one-time benefits (tariff recovery) supporting margins. Management is focused on upgrades, scaling launch teams, and patient-activation initiatives to drive durable utilization improvements.Company Guidance
Top-line Revenue and Procedure Growth
Total revenue of $94.5M in Q2 2026, up 19% year-over-year; U.S. revenue $83.4M, up 20% YoY. U.S. procedures exceeded 13,100 in the quarter, up ~21% YoY.
Strong HYDROS System Demand and Adoption
Placed 65 HYDROS systems in the U.S. during Q2 (50 greenfield, 14 replacements, 1 operating lease). HYDROS accounts showed materially stronger early utilization versus legacy AQUABEAM accounts.
Record System Pricing
Q2 U.S. HYDROS system ASP ~ $495,000 (up from $485,000 in Q1 and $435,000 in FY2025), described as the highest to date and signaling strong pricing validation from customers.
Consumables / AMP Alignment with Procedures
AMPs represented ~98% handpiece-to-procedure ratio in the quarter. Handpiece and consumables revenue was $48.4M, up 12% YoY, with handpiece ASP ~ $3,550.
Profitability Path and Balance Sheet Strength
Gross margin improved to 66% in Q2 (vs. 65% prior year) and management reiterated full-year gross margin target ~65%. Cash, cash equivalents and restricted cash totaled $231M as of June 30, 2026. Company expects positive adjusted EBITDA in Q4 2026.
Clinical and Regulatory Milestones
American Urology Association strengthened its recommendation for Aquablation; completed enrollment in WATER IV randomized trial (280 patients); received FDA IDE approval for WATER IV AF (up to 333 patients). Aquablation supported by ~250 peer-reviewed publications.
Commercial Execution — Launch Team & DTC Initiatives
Dedicated launch team rollout accelerated (launch-team-sourced HYDROS placements rose to ~40% in Q2 from ~20% in Q1). Direct-to-patient/patient-activation pilots are active in 18 U.S. markets with encouraging leading indicators (increased website traffic, digital engagement, patient inquiries).
Full-Year 2026 Guidance Reflects Continued Growth
Full-year revenue guidance of $390M–$410M (growth ~27%–33% vs 2025). U.S. procedure guidance of 54,000–56,000 (growth ~25%–29% YoY). International revenue expected $50M–$51M.
PRCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed